Published in Cancer Treat Res on January 01, 2005
Listeria-based vaccines can overcome tolerance by expanding low avidity CD8+ T cells capable of eradicating a solid tumor in a transgenic mouse model of cancer. Cancer Immun (2007) 1.06
Bridging innate and adaptive antitumor immunity targeting glycans. J Biomed Biotechnol (2010) 0.84
Analysis of T-cell receptor-gamma gene rearrangements using oligonucleotide microchip: a novel approach for the determination of T-cell clonality. J Mol Diagn (2007) 0.78
Risk of thyroid cancer based on thyroid ultrasound imaging characteristics: results of a population-based study. JAMA Intern Med (2013) 3.62
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother (2007) 3.16
Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT. BMC Immunol (2005) 2.31
A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med (2005) 2.26
Adenovirus infection triggers a rapid, MyD88-regulated transcriptome response critical to acute-phase and adaptive immune responses in vivo. J Virol (2006) 2.16
Maximizing the retention of antigen specific lymphocyte function after cryopreservation. J Immunol Methods (2005) 2.16
Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood (2008) 2.13
Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II. Mol Ther (2005) 1.87
An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer. J Clin Invest (2010) 1.71
Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium. Cancer Immunol Immunother (2009) 1.63
Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides. BMC Immunol (2008) 1.60
Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected]. J Transl Med (2012) 1.59
Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations. Cancer Res (2011) 1.58
Carotid atherosclerosis does not predict coronary, vertebral, or aortic atherosclerosis in patients with acute stroke symptoms. Stroke (2010) 1.48
Enumerating antigen-specific T-cell responses in peripheral blood: a comparison of peptide MHC Tetramer, ELISpot, and intracellular cytokine analysis. J Immunother (2004) 1.40
CD8-independent tumor cell recognition is a property of the T cell receptor and not the T cell. J Immunol (2003) 1.38
HER2 overexpression elicits a proinflammatory IL-6 autocrine signaling loop that is critical for tumorigenesis. Cancer Res (2011) 1.38
Immunomodulatory gene therapy prevents antibody formation and lethal hypersensitivity reactions in murine pompe disease. Mol Ther (2009) 1.34
Investigation of HIFU-induced anti-tumor immunity in a murine tumor model. J Transl Med (2007) 1.33
Dendritic cell-based immunotherapy. Int Rev Immunol (2006) 1.30
Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clin Cancer Res (2005) 1.28
CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer. J Natl Cancer Inst (2010) 1.26
Increasing vaccine potency through exosome antigen targeting. Vaccine (2011) 1.13
Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy. Expert Opin Biol Ther (2007) 1.12
Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2. J Transl Med (2007) 1.11
Immunodominant liver-specific expression suppresses transgene-directed immune responses in murine pompe disease. Hum Gene Ther (2012) 1.08
CPG-7909 (PF-3512676, ProMune): toll-like receptor-9 agonist in cancer therapy. Expert Opin Biol Ther (2007) 1.07
Release of endogenous danger signals from HIFU-treated tumor cells and their stimulatory effects on APCs. Biochem Biophys Res Commun (2005) 1.07
CpG oligodeoxynucleotides as TLR9 agonists: therapeutic applications in cancer. BioDrugs (2009) 1.06
Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors. Mol Cancer Ther (2011) 0.96
Priming and activation of human ovarian and breast cancer-specific CD8+ T cells by polyvalent Listeria monocytogenes-based vaccines. J Immunother (2009) 0.95
Dendritic cell vaccines. Front Biosci (2007) 0.95
Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA. Cancer Invest (2003) 0.95
An adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicty and enhanced therapeutic efficacy without oncogenicity. Clin Cancer Res (2010) 0.94
Replication-attenuated Human Adenoviral Type 4 vectors elicit capsid dependent enhanced innate immune responses that are partially dependent upon interactions with the complement system. Virology (2008) 0.94
Conservative management of cesarean scar pregnancy with sonographically guided transvaginal methotrexate injection. J Ultrasound Med (2013) 0.93
MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancer. Clin Cancer Res (2011) 0.93
T cell avidity and tumor recognition: implications and therapeutic strategies. J Transl Med (2005) 0.93
Monobenzyl ether of hydroquinone and 4-tertiary butyl phenol activate markedly different physiological responses in melanocytes: relevance to skin depigmentation. J Invest Dermatol (2010) 0.93
Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo. Int J Cancer (2010) 0.93
T-cell receptor tetramer binding or the lack there of does not necessitate antigen reactivity in T-cell receptor transduced T cells. Cancer Immunol Immunother (2005) 0.91
Current status of adoptive immunotherapy of malignancies. Expert Opin Biol Ther (2002) 0.91
CD34-based enrichment of genetically engineered human T cells for clinical use results in dramatically enhanced tumor targeting. Cancer Immunol Immunother (2010) 0.90
Influence of human CD8 on antigen recognition by T-cell receptor-transduced cells. Cancer Res (2006) 0.89
Multiple signals are required for maturation of human dendritic cells mobilized in vivo with Flt3 ligand. J Leukoc Biol (2002) 0.89
NKG2D signaling on CD8⁺ T cells represses T-bet and rescues CD4-unhelped CD8⁺ T cell memory recall but not effector responses. Nat Med (2012) 0.89
Identification of a hepatitis C virus-reactive T cell receptor that does not require CD8 for target cell recognition. Hepatology (2006) 0.89
Melanoma-associated antigen expression in lymphangioleiomyomatosis renders tumor cells susceptible to cytotoxic T cells. Am J Pathol (2009) 0.88
Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients. Cancer Immunol Immunother (2013) 0.88
Immunoregulatory T cells in cancer immunotherapy. Expert Opin Biol Ther (2002) 0.88
Ex vivo expanded human CD4+ regulatory NKT cells suppress expansion of tumor antigen-specific CTLs. Int Immunol (2005) 0.87
Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cells. Breast Cancer Res (2012) 0.87
New perspectives on zoledronic acid in breast cancer: potential augmentation of anticancer immune response. Cancer Invest (2011) 0.86
The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer. Int J Gastrointest Cancer (2002) 0.86
ICOS costimulation expands Th2 immunity by augmenting migration of lymphocytes to draining lymph nodes. J Immunol (2008) 0.86
Evidence for phenotypic plasticity in aggressive triple-negative breast cancer: human biology is recapitulated by a novel model system. PLoS One (2012) 0.85
Update on anti-CTLA-4 antibodies in clinical trials. Expert Opin Biol Ther (2007) 0.85
Characterization of MHC class-I restricted TCRalphabeta+ CD4- CD8- double negative T cells recognizing the gp100 antigen from a melanoma patient after gp100 vaccination. Cancer Immunol Immunother (2008) 0.83
Dendritic cell maturation in active immunotherapy strategies. Expert Opin Biol Ther (2002) 0.83
CD28 and ICOS play complementary non-overlapping roles in the development of Th2 immunity in vivo. Cell Immunol (2009) 0.83
Recent clinical progress in virus-based therapies for cancer. Expert Opin Biol Ther (2006) 0.83
HER2 dendritic cell vaccines. Clin Breast Cancer (2003) 0.83
Fas ligand expression on T cells is sufficient to prevent prolonged airway inflammation in a murine model of asthma. Am J Respir Cell Mol Biol (2009) 0.83
Ligand-independent toll-like receptor signals generated by ectopic overexpression of MyD88 generate local and systemic antitumor immunity. Cancer Res (2010) 0.83
Role of natural killer cell function in dendritic cell-based vaccines. Expert Rev Vaccines (2006) 0.82
Induction of Wilms' tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccine. Clin Cancer Res (2009) 0.82
Recognition of carcinoembryonic antigen peptide and heteroclitic peptide by peripheral blood T lymphocytes. J Immunother (2007) 0.82
Inducible costimulator expression regulates the magnitude of Th2-mediated airway inflammation by regulating the number of Th2 cells. PLoS One (2009) 0.82
Co-delivery of antigen and IL-12 by Venezuelan equine encephalitis virus replicon particles enhances antigen-specific immune responses and antitumor effects. Cancer Immunol Immunother (2012) 0.81
A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC). Cancer Chemother Pharmacol (2014) 0.81
Targeted therapy for solid tumors: current status. Surg Oncol Clin N Am (2008) 0.81
An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors. Cancer Chemother Pharmacol (2012) 0.80
Redirecting T lymphocyte specificity using T cell receptor genes. Int Rev Immunol (2003) 0.80
Immunotherapy of surgical malignancies. Curr Probl Surg (2004) 0.79
Depletion of human regulatory T cells. Methods Mol Biol (2011) 0.79
Relationship between CD8-dependent antigen recognition, T cell functional avidity, and tumor cell recognition. Cancer Immunol Immunother (2008) 0.79
Engagement of NK receptor NKG2D, but not 2B4, results in self-reactive CD8+ T cells and autoimmune vitiligo. Autoimmunity (2011) 0.78
Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies. Invest New Drugs (2015) 0.78
Priming with very low-affinity peptide ligands gives rise to CD8(+) T-cell effectors with enhanced function but with greater susceptibility to transforming growth factor (TGF)β-mediated suppression. Cancer Immunol Immunother (2011) 0.78
RGS3 controls T lymphocyte migration in a model of Th2-mediated airway inflammation. Am J Physiol Lung Cell Mol Physiol (2013) 0.78
Gata5 deficiency causes airway constrictor hyperresponsiveness in mice. Am J Respir Cell Mol Biol (2014) 0.77
Dendritic cell recovery following nonmyeloablative allogeneic stem cell transplants. J Hematother Stem Cell Res (2002) 0.77
CD8(+) T cells sabotage their own memory potential through IFN-γ-dependent modification of the IL-12/IL-15 receptor α axis on dendritic cells. J Immunol (2012) 0.77
CEA loaded dendritic cell vaccines. Cancer Chemother Biol Response Modif (2002) 0.77
ICOS-expressing lymphocytes promote resolution of CD8-mediated lung injury in a mouse model of lung rejection. PLoS One (2013) 0.77
The staging of gastric cancer: nothing novel but perhaps better. Ann Surg Oncol (2003) 0.77
Immunotherapeutic targeting of Wilms' tumor protein. Curr Opin Mol Ther (2007) 0.77
Immune monitoring. Cancer Treat Res (2005) 0.76
Pancreaticobiliary reflux and gallbladder cancer. J Surg Oncol (2007) 0.76
Cancer regression and neurological toxicity cases after anti-MAGE-A3 TCR gene therapy. J Immunother (2013) 0.76
Immunologic monitoring of cellular immune responses in cancer vaccine therapy. J Biomed Biotechnol (2011) 0.76
Current status of dendritic cell immunotherapy of malignancies. Int Rev Immunol (2003) 0.75
Recent areas of development for dendritic cell vaccines. Cancer Chemother Biol Response Modif (2003) 0.75
Proteomics for monitoring immune responses to cancer vaccines. Curr Opin Mol Ther (2003) 0.75
The development of therapeutic and preventive vaccines for gastric cancer and Helicobacter pylori. Cancer Epidemiol Biomarkers Prev (2005) 0.75